Journal
OPHTHALMIC PLASTIC AND RECONSTRUCTIVE SURGERY
Volume 33, Issue 3, Pages S68-S70Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/IOP.0000000000000565
Keywords
-
Categories
Ask authors/readers for more resources
Vismodegib is proven to be effective in the treatment of locally advanced and metastatic basal cell carcinoma, but evidence of resistance is beginning to emerge. A case of advanced recurrent periocular basal cell carcinoma which responded dramatically to vismodegib after 3 months but recurred after 9 months due to drug resistance, eventually requiring orbital exenteration, is presented. The mechanism of vismodegib resistance is discussed.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available